The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000541303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
26/03/2026
Date registered
Help: Date registered
30/04/2026
Date last updated
Help: Date last updated
2/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
30/04/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
A First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study on the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of EBMC-710GO in Healthy Adults who are Overweight or have Obesity
Scientific title
A First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study on the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of EBMC-710GO in Healthy Adults who are Overweight or have Obesity
Additional trial identifiers [1] 316655 0
710GO-HV-01
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Obesity 340872 0
Overweight 341482 0
Condition category
Condition code
Diet and Nutrition 337031 337031 0 0
Obesity

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The study drug, EBMC-710GO, is a peptide agonist of both melanocortin type 3 receptors (MC3R) and melanocortin type 4 receptors. The study drug is formulated as a solution for daily oral administration.

Part A: Single Ascending Dose (SAD):
Participants who are overweight or have obesity will be enrolled in one of 5 SAD cohorts with up to 8 participants per cohort. Safety and tolerability of each dose will be measured with new cohorts introduced in an ascending pattern as follows: 1.25 mg/kg; 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg. Participants will receive a single dose of EBMC-710GO (or placebo) on Day 1 of the study.

Dosing in each cohort will commence with 2 sentinel participants, whereby one of the two sentinel participants will be randomised to receive EBMC 710GO and the other randomised to receive placebo. The safety and tolerability of each sentinel participant will be monitored in the clinic. The Principal Investigator (PI) will review safety/tolerability information available on the sentinel participants at 48 hours post-dose, prior to dosing the remainder of participants in each cohort.

If the dose is found to be safe, 6 more participants will be randomised to the cohort - 5 participants will receive EBMC-710GO and one will receive placebo.

Part B: Multiple Ascending Doses (MAD):
Up to 48 participants who are overweight or have obesity will be enrolled into one of two MAD cohorts. Each cohort will enrol up to 24 participants, 18 will receive EBMC-710GO and 6 will receive placebo. The two active treatment doses will be 2.5mg/kg, or 5mg/kg, taken once daily for 28 days.

To expedite cohort progression, each cohort will enrol 2 groups of 12 participants with ratio 9:3 active:placebo for each group.

Adherence to the intervention will be monitored in participant diaries.
Intervention code [1] 333332 0
Treatment: Drugs
Description of the comparator or control
The control treatment will be a matching placebo solution comprised of ORA-Sweet (50% v/v), a bittering agent, and water for injection (50% v/v). The control treatment lacks the active ingredient but is otherwise identical to the intervention in both composition and appearance.
Control group
Placebo

Outcomes
Primary outcome [1] 344552 0
Part A - SAD: To investigate the safety and tolerability of EBMC-710GO administered as a single oral dose in a fasted state in healthy adult participants who are overweight or have obesity.
Timepoint [1] 344552 0
Part A - SAD: Adverse events - The Investigator will make an assessment of severity for each AE and SAE reported during the study. The severity of each AE and SAE will be monitored continuously throughout the trial, from first administration of IP through to the last trial related activity Vital signs will be measured using an automated device at Screening, within 60 minutes pre-dose on Day 1, and at the following post-dose intervals (prior to PK blood collection): 30 mins, 1 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, and 144 hours (at follow-up/end-of-study visit). Clinical laboratory evaluation blood samples will be collected at Screening to note baseline values, Tests will be repeated on the following days: Day 1, 2, 4 and 7 (end-of-treatment). C-SSRS Questionnaires will be completed on the following days: Baseline (Day -1), 2, 4 and 7 (end-of-treatment).
Primary outcome [2] 345053 0
Part B - MAD: To investigate the safety and tolerability of EBMC-710GO administered as multiple oral doses in a fasted state in healthy adult participants who are overweight or have obesity.
Timepoint [2] 345053 0
Part B - MAD: Adverse events - The Investigator will make an assessment of severity for each AE and SAE reported during the study. The severity of each AE and SAE will be monitored continuously throughout the trial, from first administration of IP through to the last trial related activity Vital signs will be measured using at Screening, within 60 minutes pre-dose on Day 1, and at the following post-dose intervals (prior to PK blood collection): Once per day on Days 1-7, 14, 21, 27-31, and at Follow-Up visits on Day 35 and 42. Clinical laboratory evaluation blood samples will be collected at Screening to note baseline values, Tests will be repeated on the following days: Days 1, 3, 7, 14, 21, 28, 31 and 42 (end-of-treatment). Urine samples will be collected at the following timepoints: Baseline (Day -1), Days 7, 14, 21, 28, and 31 and 42 (end-of-treatment). C-SSRS Questionnaires will be completed on the following days: Baseline (Day -1). Days 2, 7, 14, 21, 28, 31 and 42 (end-of-treatment).
Secondary outcome [1] 458390 0
Part A - SAD: To measure how the body interacts with 710GO as single oral dose in healthy adult participants who are overweight or have obesity.
Timepoint [1] 458390 0
Part A - SAD: Blood collection for PK sampling will occur at the following timepoints: Pre-dose, 30 mins, 1 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, and 144 hours (at follow-up/end-of-study visit).
Secondary outcome [2] 458907 0
Part A - SAD: To evaluate the body composition effect of a single dose of EBMC 710GO in adults who are overweight or have obesity.
Timepoint [2] 458907 0
Weight - Screening, Baseline (Day -1), pre-dose on Days 1, 2, 3, 4 and 7 (end-of-treatment). BMI - Screening, Baseline (Day -1). Hip to waist ratio - Screening, Baseline (Day -1).
Secondary outcome [3] 458908 0
Part A - SAD: Measure an exposure-response change in appetite.
Timepoint [3] 458908 0
Part A - SAD: Baseline (Day -1), post-dose (in the evening) on Days 1 and 2.
Secondary outcome [4] 458909 0
Part A - SAD: To evaluate the effect of a single dose of EBMC 710GO in adults who are overweight or have obesity on PD biomarkers - changes in skin tone.
Timepoint [4] 458909 0
Part A - SAD: Baseline (Day -1), pre-dose on Day 2, and on Day 7 (end-of-treatment).
Secondary outcome [5] 460331 0
Part B - MAD: To measure how the body interacts with 710GO as multiple oral doses in healthy adult participants who are overweight or have obesity.
Timepoint [5] 460331 0
Part B - MAD: Blood collection for PK sampling will occur at the following timepoints: Pre-dose, Once per day on Days 1-7, 14, 21, 28-31, and at follow-up visits on Day 35 and 42.
Secondary outcome [6] 460332 0
Part B - MAD: To evaluate the body composition effect of multiple doses of EBMC 710GO in adults who are overweight or have obesity.
Timepoint [6] 460332 0
Weight - Screening, Days 1-7, 14, 21, 27-31, 35, 42 (end-of-treatment), and end of study visit. BMI - Screening, Days 1-7, 14, 21, 27-31, 35, 42 (end-of-treatment), and end of study visit. Hip to waist ratio - Screening, Baseline (Day -1), Days 14, 28, 42 (end-of-treatment), and end-of-study visit.
Secondary outcome [7] 460333 0
Part B - MAD: Measure an exposure-response change in appetite.
Timepoint [7] 460333 0
Part B - MAD: Baseline (Day -1), post-dose (in the evening) on Days 1, 2, 5, 6, 14 and 21, and on Days 35 and 42 (end-of-treatment).
Secondary outcome [8] 460334 0
Part B - MAD: To evaluate the effect of multiple doses of EBMC 710GO in adults who are overweight or have obesity on PD biomarkers - changes in skin tone.
Timepoint [8] 460334 0
Part B - MAD: Baseline (Day -1), pre-dose on Day 28, and on Day 42 (end-of-treatment).

Eligibility
Key inclusion criteria
Adult males and females, 18 to 55 years of age (inclusive) at screening.
Body mass index (BMI): Between 25.0 and 40.0 kg/m2 (inclusive),
Medically healthy (in the opinion of the PI or delegate), as determined by pre-study medical history, and without clinically significant (CS) abnormalities.
Female volunteers must be of non-child-bearing potential, or willing to use adequate contraception and give a negative pregnancy test at screening.
Male volunteers must not donate sperm from the date of signing the consent form until at least 91 days after the last dose of the study drug, and must agree to use adequate forms of contraception with female partners.
Have suitable venous access for blood sampling.
Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.
Hip-to-waist ratio >0.9 for males or >0.85 for females.
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
Known hypersensitivity to the study drug or any of the study drug ingredients.
History of anaphylaxis or other significant allergy (i.e., multiple food or drug allergies) which, in the opinion of the PI (or delegate), would interfere with the volunteer’s ability to participate in the study.
History or presence of CS cardiovascular (including active hypertension and/or history of poor or uncontrolled hypertension), pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic, psychiatric, or neurological disease/disorder, within the past 3 months determined by the PI (or delegate) to be clinically relevant.
History or current diagnosis with type 1 or type 2 diabetes mellitus.
History or presence of clinically relevant oesophageal or gastrointestinal disease/disorders, including (but not limited to) cholecystectomy, pancreatitis, irritable bowel syndrome, and inflammatory bowel disease. Note: A history of gastroesophageal reflux disease is not exclusionary.
History of hypo/hyperthyroidism (except those undergoing replacement with thyroxine and on a stable dose for the at least 2 months at the time of screening), repeated thyroid stimulating hormone (TSH) values that are abnormal at screening, or obesity of endocrine origin.
Presence or sequelae of gastrointestinal, liver (including Gilbert’s syndrome), kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs (e.g., over or under production of clinical or laboratory assessments).
Any CS (as determined by PI [or delegate]) disorders of skin and hair follicle pigmentation (including but not limited to albinism and vitiligo), and CS dermatological conditions (e.g., eczema).
A CS acute illness within 1 week prior to dosing.
History of surgical treatment for obesity or any other major gastrointestinal surgery (as determined by the PI [or delegate]).
History of surgery or hospitalisation within 6 months prior to screening, or surgery planned during the study. If a previous surgical procedure was performed within 6 months and a full recovery was made with no expected impact on study procedures or participant safety, the participant may be eligible at the discretion of the PI and Medical Monitor.
Any history of malignant disease in the last 10 years except for fully resolved surgically resected skin squamous or basal cell carcinoma or cervical intraepithelial neoplasia.
History of cardiac abnormalities, including a family history of long QT syndrome and/or family history of sudden death in an otherwise healthy individual between the ages of 1 and 30 years.
Abnormal and clinically relevant ECG characteristics at Screening including, but not limited to:
a. bradycardia or tachycardia (sinus rate 100 bpm)
b. complete left bundle branch block
c. complete right bundle branch block
d. second- or third-degree heart block
e. intraventricular conduction delay with QRS duration >120 ms, QTcF duration >450 msec (males) or >470 msec (females)
f. pathological Q-wave
g. symptomatic or asymptomatic arrhythmias (excluding sinus arrhythmia)
h. evidence of ventricular pre-excitation
i. frequent palpitations or syncopal episodes
j. heart failure (i.e., all stages of diagnosed heart failure)
Any CS neurological or psychiatric diagnosis or psychological or behavioural problems (e.g., major depression, anxiety, suicidal behaviour or attempts, or other psychiatric disorder) that, in the opinion of the investigator, would interfere with the participant’s ability to participate in the study.
Any suicidal ideation with intent, with or without a plan, within 2 years before screening or during screening (i.e., answering “Yes” to questions 4 or 5 on the Suicidal Ideation section of the C-SSRS).
Presence of clinically relevant immunosuppression including, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia.
Liver function test results elevated more than 1.5-fold above the ULN for gamma glutamyl transferase, bilirubin (total, conjugated), ALP, AST or ALT. Volunteers with ALP and/or ALT or AST above the limits specified may be included, at the discretion of the PI (or delegate), if unaccompanied by clinical signs and are determined to be normal variants.
Serum creatinine above the ULN.
Fibrinogen above the ULN.
A history of or positive test results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies at the screening visit.
History of alcohol or illicit drug abuse.
Positive drugs of abuse test, cotinine test, or alcohol breath test results at the screening visit and/or on admission to the study site on Day 1.
Regular consumption of more than 14 standard alcoholic drinks/week and/or more than 4 standard alcoholic drinks on any one day, where 1 standard drink is 10 g of pure alcohol and is equivalent to 285 mL beer [4.9% Alc/Vol], 100 mL wine [12% Alc/Vol], or 30 mL spirit [40% Alc/Vol]), and/or the volunteer is unwilling to abstain from alcohol for at least 24 hours prior to check-in to the study site, while confined to the study site, and for at least 24 hours prior to an outpatient appointment.
Volunteer smokes more than 5 cigarettes or equivalent nicotine-containing products per week, and/or the volunteer is unwilling to abstain from smoking or the use of nicotine-containing products for 72 hours prior to check-in to the study site, throughout the confinement period(s) at the study site, for the duration of the treatment period, and for 72 hours prior to each outpatient appointment.
Note: 1 average cigar is equal to approx. 5 average cigarettes; 1 average pipe session is equal to approx. 5 average cigarettes; 1 average nicotine liquid vape session is equal to 1 average e-cigarette or 1 average cigarette.
A heavy caffeine drinker (consume equivalent of >5 cups or glasses of caffeinated beverages [e.g., coffee, tea, cola, energy drink] per day), and/or the volunteer is unwilling to abstain from the consumption of caffeine and/or xanthene products for at least 24 hours prior to check-in to the study site, while confined to the study site, and for at least 24 hours prior to an outpatient appointment.
Females who are breastfeeding or planning to breastfeed.
Unable to swallow oral medication.
Use of weight-lowering pharmacotherapy (including dietary aids or supplements), or dieting and organised weight loss program within 3 months prior to screening. Note: Regular physical exercise is permitted upon consultation with the PI.
Use of any prescription or over-the-counter medication (including herbal products, vitamins, hormone supplements, homeopathic preparations, cannabinoids) within 14 days or 5 half-lives of the medication (whichever is longer) prior to the first dose of IP. The following are permitted: use of contraceptives, use of paracetamol (up to 2 g per day) for no more than 3 consecutive days, use of ibuprofen (up to 600 mg per day) for no more than 3 consecutive days, and use of medications for gastroesophageal reflux disease (e.g., H2 blockers or proton pump inhibitors) except for 24 hours prior to IP administration.
Current infection that requires systemically absorbed antibiotic, antifungal, antiparasitic, or antiviral medication within 10 days prior to first dose of IP.
Received vaccination(s) within 14 days prior to dosing or has vaccination(s) planned during the study.
Donation of blood or plasma within 90 days prior to first dose of the study drug, or loss of whole blood of more than 500 mL within 90 days prior to first dose of the study drug, or receipt of a blood transfusion within 1 year of the first dose of the study drug.
Participation in another clinical study of an investigational drug or investigational device within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to screening. Note: Participants may only participate once (i.e., in one cohort) in the current study.
Any other condition or prior therapy that in the opinion of the PI (or delegate) would pose a risk or make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All study participants who sign an informed consent form (ICF) will receive a unique sequential number (i.e., a screening number).

Participants who meet the study eligibility criteria will be assigned a randomisation number, which corresponds to a study treatment (EBMC 710GO or placebo), in accordance with the randomisation schedule. The randomisation schedule will be prepared by unblinded statistician(s) and will be maintained under controlled access. Blinded study staff will not have access to the randomisation schedule until after database lock.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Allocation to EBMC 710GO or placebo will be performed using a block randomisation algorithm. In addition, for Part B (MAD Cohort), the randomisation will assign participants into 2 groups of 12 participants each.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 321266 0
Commercial sector/Industry
Name [1] 321266 0
Kalohexis
Country [1] 321266 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
Kalohexis
Address
Country
United States of America
Secondary sponsor category [1] 323977 0
Commercial sector/Industry
Name [1] 323977 0
Avance Clinical Pty Ltd
Address [1] 323977 0
Country [1] 323977 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319795 0
Bellberry Human Research Ethics Committee A
Ethics committee address [1] 319795 0
Ethics committee country [1] 319795 0
Australia
Date submitted for ethics approval [1] 319795 0
25/02/2026
Approval date [1] 319795 0
10/04/2026
Ethics approval number [1] 319795 0
2026-02-213

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148426 0
Dr Michael Wong
Address 148426 0
Q-Pharm Pty Ltd, Level 5, Clive Berghofer Cancer Research Centre (CBRC Building), 300C Herston Rd, Herston QLD 4006, Australia
Country 148426 0
Australia
Phone 148426 0
+61 07 3707 2720
Fax 148426 0
Email 148426 0
Contact person for public queries
Name 148427 0
Dr Michael Wong
Address 148427 0
Q-Pharm Pty Ltd, Level 5, Clive Berghofer Cancer Research Centre (CBRC Building), 300C Herston Rd, Herston QLD 4006, Australia
Country 148427 0
Australia
Phone 148427 0
+61 07 3707 2720
Fax 148427 0
Email 148427 0
Contact person for scientific queries
Name 148428 0
Dr Michael Wong
Address 148428 0
Q-Pharm Pty Ltd, Level 5, Clive Berghofer Cancer Research Centre (CBRC Building), 300C Herston Rd, Herston QLD 4006, Australia
Country 148428 0
Australia
Phone 148428 0
+61 07 3707 2720
Fax 148428 0
Email 148428 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.